Trial Profile

Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tusamitamab ravtansine (Primary) ; Gemcitabine
Indications Adenocarcinoma; Advanced breast cancer; Pancreatic ductal carcinoma; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms CARMEN-BT01
Sponsors Sanofi

25 Mar 2025 Status changed from active, no longer recruiting to completed.
13 Aug 2024 Planned End Date changed from 1 Oct 2024 to 18 Nov 2024.
07 May 2024 Planned primary completion date changed from 16 Apr 2024 to 30 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com